Catalina Vasquez and Colin Coros at JPM Week 2023
perrin2023-01-06T00:53:33+00:00JPM Week 2023
Date: January 9 to 12
Venue: In-person, San Francisco, CA
Press Release: Nanostics Announces New Member of Board of Directors
perrin2022-11-17T14:38:46+00:00Edmonton, Alberta – Nanostics Inc., a precision health diagnostics company, announced today the appointment of Aubrey Rankin to its Board of Directors. Mr. Rankin will join the board of directors at Nanostics replacing Mr. Reg Joseph as one of the independent directors for the company.
“We’re excited to announce Aubrey Rankin’s appointment to Nanostics’ Board of Directors. Aubrey’s vast experience and insights with patient-provider subscription platforms will be invaluable as we launch our lead prostate cancer diagnostic test, ClarityDX Prostate®,” said John Lewis, CEO of Nanostics.
Nanostics sends thanks to outgoing board member Reg Joseph, CEO of Health City, for his service. Reg’s insights into the Healthcare Industry were instrumental in helping Nanostics advance its lead diagnostic product, ClarityDX Prostate® through clinical studies and position it for regulatory approval.
Desmond Pink at ISEVxTech
perrin2022-11-17T06:10:34+00:00ISEVxTech Conference
Date: November 16 to 18
Venue: In-person, Waikiki Beach Marriot Resort, Honolulu, HI
1. Qualifying EV Technologies for Regulated and non-Regulated Research
2. Multi-angle flow cytometry illustrates the refractive index complexity
of commonly evaluated biological samples for extracellular vesicle analysis
perrin2022-11-22T17:07:22+00:00
CanPath Webinar with Dr. John Lewis
WEBINAR TO BE RESCHEDULED
Webinar: Predicting diseases through machine learning models
Date: Tuesday, November 22. 2022. New date TBD – please check back for updates.
Venue: Online – for more details and to register go to Event Link
Can Machine Learning models predict disease? Dr. John Lewis, Bird Dogs Chair in Translational Oncology at the University of Alberta, and CEO of Nanostics will talk about creating disease prediction models using CanPath questionnaire data, to help us understand the global risk factors of diseases like prostate cancer and how these risk factors differ for different populations.
News Release: Recognizing 10 years of philanthropic support for prostate cancer research
perrin2022-10-13T05:02:22+00:00Two powerhouse researchers in prostate cancer will change the way we treat the disease, thanks to funding from legendary volunteer fundraisers, the Bird Dogs and the Alberta Cancer Foundation.
Working with the Alberta Cancer Foundation and the University of Alberta, the Bird Dogs have enabled a new one-term, five-year chair position to further prostate cancer research — the Bird Dogs Chair in Translational Oncology, a position to be held by researcher Dr. John Lewis. For the last 10 years, Dr. Lewis has held the Frank and Carla Sojonky Chair in Prostate Cancer Research, made possible by a $5 million endowment from the Bird Dogs. Taking over from Dr. Lewis in this position will be surgeon-scientist, Dr. Adam Kinnaird.
Amii Artificial Intelligence Virtual Seminar Series
perrin2022-09-02T06:12:20+00:00What: Nanostics’ CTO Robert Paproski will present “Lessons Learned Developing Predictive Models for Healthcare”
When: September 2, 12-1 pm MT
Go here to access the zoom link and password (scroll to Sept 2) https://sites.google.com/ualberta.ca/ai-seminar/upcoming-seminars
Abstract:
Over the past decade, significant interest has developed for using machine learning in medical devices for assisting in the diagnosis and risk prediction of diseases. Many publications have demonstrated promising preliminary results although the path of deploying a predictive model in the clinic is challenging from a technological and regulatory perspective. This presentation will discuss Nanostics’ work developing ClarityDX Prostate, a medical device which predicts clinically significant prostate cancer, including the challenges of obtaining FDA approval. Training predictive models on large, diverse, clinical datasets is vital for developing trustworthy models although obtaining such datasets can be problematic. Potential solutions for working with large clinical datasets will be discussed.
Press Release: Nanostics Receives CE Mark for its ClarityDX Prostate® Test to Detect Clinically Significant Prostate Cancer
perrin2022-08-23T12:18:30+00:00- Nanostics’ biomarker and machine learning-powered test, ClarityDX Prostate®, received a CE-IVD Mark.
- A CE-IVD Mark is required for all in vitro diagnostic (IVD) devices to be placed in the European Economic Area, Iceland, Norway, and Liechtenstein and allows Nanostics to market and sell ClarityDX Prostate® in these countries.
- The ClarityDX Prostate® test provides patients and physicians with an accurate prediction of clinically significant prostate cancer to support decision-making and improve health outcomes for men suspected of having prostate cancer.
Press Release: Nanostics Announces the Launch of its Bladder Cancer Clinical Study Identifying Disease Predictors for Early Detection of Bladder Cancer
perrin2022-07-20T13:09:06+00:00- Clinical study launched in June 2022 with patient recruitment in Alberta with plans to expand to further sites across North America.
- The aim of the study is to validate a novel and minimally invasive liquid biopsy test for bladder cancer diagnosis using Nanostics’ ClarityDX® diagnostic platform.
- The study is supported in part by the Alberta Innovates AICE-Concepts Program with a $600,000 award to Dr. John Lewis, Bird Dogs Chair in Translational Cancer Research at the University of Alberta.
Press Release: Nanostics Announces Study Data Supporting ClarityDX Prostate as a Reflex Test to Predict Clinically Significant Prostate Cancer
perrin2022-06-30T12:14:03+00:00Real-world data shows that at a 94% sensitivity level for prostate cancer ClarityDX Prostate® is 147% more specific than the PSA test for predicting clinically significant prostate cancer. Using ClarityDX Prostate® as a reflex test vs. PSA test alone could have resulted in 37% fewer unnecessary biopsies.
Liquid biopsy EV analysis with small particle flow cytometry
perrin2022-09-02T06:29:31+00:00Click here for CYTO 2022 POSTER PRESENTATION
Click here for CYTO 2022 SLIDE PRESENTATION
Small particle flow cytometry using 3 light scatter detectors enhances extracellular vesicle analysis in liquid biopsies, highlighting the potential to segregate EVs by refractive index
Pink, Desmond, Basu, Arghya, Valencia, Juliana, Pham, Diana, and Lewis, J.D.
Extracellular vesicle analysis using “small particle” flow cytometry would be greatly enhanced if data from materials of different refractive index (RI) could be segregated. Likewise, relative sizing of EVs using small particle flow cytometry is confounded by the influence of RI on light scatter. Beads of different composition and refractive index scatter light differently, so that small beads of high RI and large beads of lower RI can have overlapping signals on a two dimension light scatter plot. As particle size decreases, light scatter intensity profiles eventually merge regardless of refractive index. In this project, we aimed to demonstrate graphically, (1) the enhancement of EV flow analysis when using an additional angle of light scatter collection (medium angle of light scatter, MALS) to identify different sample components (e.g. lipids, protein, extracellular vesicles) and (2) the practical reality of sample component overlap at different particle sizes.
Nanostics CSO Desmond Pink will be presenting this work at CYTO 2022, June 3-7, in Philadelphia, US.
CYTO 2022 MOVING FORWARD
Empowering Scientists. Advancing Cytometry.
